JP2023504786A - 抗がん効果増進のためのERRγ抑制剤を有効成分として含む組成物の用途 - Google Patents
抗がん効果増進のためのERRγ抑制剤を有効成分として含む組成物の用途 Download PDFInfo
- Publication number
- JP2023504786A JP2023504786A JP2022530915A JP2022530915A JP2023504786A JP 2023504786 A JP2023504786 A JP 2023504786A JP 2022530915 A JP2022530915 A JP 2022530915A JP 2022530915 A JP2022530915 A JP 2022530915A JP 2023504786 A JP2023504786 A JP 2023504786A
- Authority
- JP
- Japan
- Prior art keywords
- liver cancer
- sorafenib
- errγ
- gene
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 22
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 12
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title claims description 32
- 239000003112 inhibitor Substances 0.000 title abstract description 26
- 201000007270 liver cancer Diseases 0.000 claims abstract description 240
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 239
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims abstract description 234
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims abstract description 234
- 229960003787 sorafenib Drugs 0.000 claims abstract description 233
- 108091008557 estrogen-related receptor gamma Proteins 0.000 claims abstract description 203
- 102100031855 Estrogen-related receptor gamma Human genes 0.000 claims abstract description 130
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 100
- 230000014509 gene expression Effects 0.000 claims description 96
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 108020004999 messenger RNA Proteins 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 66
- 238000011282 treatment Methods 0.000 claims description 42
- 239000012472 biological sample Substances 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 26
- 238000003745 diagnosis Methods 0.000 claims description 17
- 230000004952 protein activity Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 229940125425 inverse agonist Drugs 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 14
- 108091023037 Aptamer Proteins 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000003757 reverse transcription PCR Methods 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 7
- 108020004459 Small interfering RNA Proteins 0.000 claims description 7
- 230000002411 adverse Effects 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 108091070501 miRNA Proteins 0.000 claims description 7
- 239000002679 microRNA Substances 0.000 claims description 7
- 238000000018 DNA microarray Methods 0.000 claims description 6
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 6
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 210000003494 hepatocyte Anatomy 0.000 claims description 6
- 239000002924 silencing RNA Substances 0.000 claims description 6
- 239000004055 small Interfering RNA Substances 0.000 claims description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000002860 competitive effect Effects 0.000 claims description 4
- 210000005228 liver tissue Anatomy 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 83
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 24
- 239000000126 substance Substances 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 18
- 238000010171 animal model Methods 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- -1 hydrochloric Chemical class 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 4
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004797 therapeutic response Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000003317 immunochromatography Methods 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Description
(a)ソラフェニブに対して耐性を示すかを確認しようとする肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、一般肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断する段階。
(a)肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、一般肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断する段階。
(a)肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、一般肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断し、ソラフェニブ以外の他の肝がん治療剤を適用する段階。
(a)ソラフェニブに対して耐性を示すかを確認しようとする肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、一般肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断する段階。
(a)肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、一般肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断する段階。
(a)肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、一般肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断し、ソラフェニブ以外の他の肝がん治療剤を適用する段階。
一般的な実験方法
本発明者らは、ソラフェニブ耐性肝がん細胞株(Huh7-SR cell line,SK-Hep-R cell line)と肝がん細胞株由来動物モデル(xenograft)を活用して実験を行った。ERRγ逆作用剤(inverse agonist)である合成化合物DN200434が肝がん細胞の増殖およびROSに及ぼす影響を確認するために、細胞計数(cell count)とDCF-DA(2’,7’-dichlorofluorescin diacetate)を用いてROSを測定した。最後に、ソラフェニブ耐性肝がん細胞株を白マウスに注入して、ソラフェニブ耐性肝がんの形成を誘導した後、ERRγ逆作用剤DN200434とソラフェニブを注入したグループおよび対照薬物を注入したグループにおいて肝がんのサイズ変化を確認した。
ソラフェニブ耐性肝がん細胞株構築とERRγ発現増加の確認
肝がん細胞株[Huh7 cell(韓国細胞株バンクKCLB No.60104)、SK-Hep cell(ATCC(登録商標)HTB-52TM)]を持続的にソラフェニブに露出させて(10μMまで徐々に増量)、ソラフェニブ耐性肝がん細胞株(Huh7-SR cell line,SK-Hep-R cell line))を構築した。まず、FACSでがん細胞死滅を評価するために、がん細胞株をFITC-結合アネキシン(Annexin)およびヨウ化プロピジウム(propidium iodide,PI)に15分間培養後、フローサイトメトリー(flow cytometry)でアネキシンとPI結合を測定して、BD accuri C6フローサイトメトリー装置(BD biosciences)を用いてデータを獲得し、Accuri C6分析プログラム(BD Biosciences)/FlowJoソフトウェア(FlowJo,LLC.)で分析した。切断されたカスパーゼ-3抗体(Cleaved caspase-3 antibody)(Cell Signaling Technology)を用いてがん細胞株死滅を評価したが、図1a~図1cに示されたように、ソラフェニブ耐性肝がん細胞株であるHuh7-SR細胞株およびSK-Hep-R細胞株は、いずれも、ソラフェニブによって細胞死滅が増加しないことを確認した。
孤児核受容体ERRγがソラフェニブ耐性肝がんに及ぼす影響の糾明
ERRγ逆作用剤である化学式1で表される化合物DN200434がソラフェニブ耐性肝がん細胞のROS生成に及ぼす影響を糾明するために、ROSプローブであるH2-DCF-DA(2’,7’-dichlorohydrofluorescein diacetate;Invitrogen、米国)を用いてFACSで測定した。ソラフェニブ(10μM)とDN200434化合物(12μM)を薬剤耐性細胞に24時間処理した後、10μMのH2-DCF-DAを細胞に添加して30分間培養し、PBSで洗浄後、BD AccuriTM C6フローサイトメトリー装置(BD Bioscience、米国)を用いてデータを収集し、AccuriTM C6分析プログラム(BD Bioscience、米国)を用いて分析した。細胞数の評価は、ソラフェニブ耐性肝がん細胞株にソラフェニブ(10μM)およびDN200434化合物(12μM)を併用処理して、トリパンブルー(Trypan blue)で染色後、細胞計数装置(Hemocytometer)を用いて細胞数を測定した。
ソラフェニブ耐性肝がん動物モデルでの抗がん効果の確認
ソラフェニブ耐性肝がん細胞株Huh7-Rをマウスに注入してソラフェニブ耐性肝がん動物モデル(xenograft)を構築し、その後、ERRγ逆作用剤、DN200434(化学式1)をソラフェニブと併用投与した後、形成された腫瘤のサイズ変化を測定した。ここで、ソラフェニブ耐性肝がん動物モデルにソラフェニブだけを処理した群を比較対照群として用いた。
Claims (34)
- ERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤を有効成分として含む、ソラフェニブ(Sorafenib)耐性肝がんの予防用または治療増進用薬学的組成物。
- 前記ERRγタンパク質の活性を抑制する製剤は、ERRγに対する逆作用剤(Inverse agonist)または拮抗剤(antagonist)、またはERRγに特異的に結合できる抗体またはアプタマーであることを特徴とする請求項1に記載の薬学的組成物。
- 前記ERRγ遺伝子の発現を抑制する製剤は、前記遺伝子のmRNAに特異的に結合するmiRNA、siRNA、shRNAおよびアンチセンスオリゴヌクレオチドからなる群から選ばれることを特徴とする請求項1に記載の薬学的組成物。
- 前記組成物は、肝がんのソラフェニブに対する薬物感受性(susceptibility)を増進させたり、またはソラフェニブの肝がんに対する抗がん効果を増進させることを特徴とする請求項1に記載の薬学的組成物。
- 前記組成物は、ソラフェニブと同時に(simultaneous)、別に(separate)または順次に(sequential)投与されることを特徴とする請求項1に記載の薬学的組成物。
- ERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤を有効成分として含む、肝がんのソラフェニブ耐性抑制用薬学的組成物。
- ERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤;およびソラフェニブを有効成分として含む、肝がんの予防または治療用薬学的組成物。
- ERRγ(Estrogen-related receptorγ)遺伝子のmRNAまたはこれから発現するタンパク質のレベルを測定する製剤を含む、ソラフェニブ耐性肝がん診断用キット。
- 前記遺伝子のmRNAレベルを測定する製剤は、前記遺伝子に特異的に結合するプライマーペア、プローブまたはアンチセンスヌクレオチドを含むことを特徴とする請求項9に記載のソラフェニブ耐性肝がん診断用キット。
- 前記タンパク質のレベルを測定する製剤は、前記タンパク質に特異的な抗体またはアプタマーを含むことを特徴とする請求項9に記載のソラフェニブ耐性肝がん診断用キット。
- 前記キットは、RT-PCRキット、競合的RT-PCRキット、リアルタイムRT-PCRキット、DNAチップキットまたはタンパク質チップキットであることを特徴とする請求項9に記載のソラフェニブ耐性肝がん診断用キット。
- 下記の段階を含むソラフェニブ耐性肝がんの診断のための情報提供方法:
(a)ソラフェニブに対して耐性を示すかを確認しようとする肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断する段階。 - 前記生物学的試料は、肝組織、肝細胞、全血、血漿、血清または血液であることを特徴とする請求項13に記載のソラフェニブ耐性肝がんの診断のための情報提供方法。
- ERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤を個体に投与する段階を含む、ソラフェニブ耐性肝がんの予防または治療増進方法。
- 前記ERRγタンパク質の活性を抑制する製剤は、ERRγに対する逆作用剤(Inverse agonist)または拮抗剤(antagonist)、またはERRγに特異的に結合できる抗体またはアプタマーであることを特徴とする請求項15に記載のソラフェニブ耐性肝がんの予防または治療増進方法。
- 前記ERRγ遺伝子の発現を抑制する製剤は、前記遺伝子のmRNAに特異的に結合するmiRNA、siRNA、shRNAおよびアンチセンスオリゴヌクレオチドからなる群から選ばれることを特徴とする請求項15に記載のソラフェニブ耐性肝がんの予防または治療増進方法。
- 前記製剤は、肝がんのソラフェニブに対する薬物感受性(susceptibility)を増進させたり、またはソラフェニブの肝がんに対する抗がん効果を増進させることを特徴とする請求項15に記載のソラフェニブ耐性肝がんの予防または治療増進方法。
- 前記製剤は、ソラフェニブと同時に(simultaneous)、別に(separate)または順次に(sequential)投与されることを特徴とする請求項15に記載のソラフェニブ耐性肝がんの予防または治療増進方法。
- ERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤を個体に投与する段階を含む、肝がんのソラフェニブ耐性抑制方法。
- ERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤;およびソラフェニブを有効成分として含む、肝がんの予防または治療方法。
- 下記の段階を含む肝がん患者の治療法の決定に必要な情報を提供する方法:
(a)肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断する段階。 - 前記生物学的試料は、肝組織、肝細胞、全血、血漿、血清または血液であることを特徴とする請求項23に記載の肝がん患者の治療法の決定に必要な情報を提供する方法。
- 下記の段階を含むソラフェニブ耐性肝がんの診断および治療方法:
(a)肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;
(b)ソラフェニブ耐性肝がんでなく、肝がん患者から分離した生物学的試料でERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルを測定する段階;および
(c)前記段階(a)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルが、前記段階(b)で測定されたERRγ遺伝子のmRNAまたはこれから発現するタンパク質の発現レベルより高い場合、前記段階(a)の肝がん患者をソラフェニブ耐性肝がん患者と判断し、ソラフェニブ以外の他の肝がん治療剤を適用する段階。 - 前記生物学的試料は、肝組織、肝細胞、全血、血漿、血清または血液であることを特徴とする請求項25に記載のソラフェニブ耐性肝がんの診断および治療方法。
- ソラフェニブ(Sorafenib)耐性肝がんの予防用または治療増進に使用するためのERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤。
- 前記ERRγタンパク質の活性を抑制する製剤は、ERRγに対する逆作用剤(Inverse agonist)または拮抗剤(antagonist)、またはERRγに特異的に結合できる抗体またはアプタマーであることを特徴とする請求項27に記載の製剤。
- 前記ERRγ遺伝子の発現を抑制する製剤は、前記遺伝子のmRNAに特異的に結合するmiRNA、siRNA、shRNAおよびアンチセンスオリゴヌクレオチドからなる群から選ばれることを特徴とする請求項27に記載の製剤。
- 前記製剤は、肝がんのソラフェニブに対する薬物感受性(susceptibility)を増進させたり、またはソラフェニブの肝がんに対する抗がん効果を増進させることを特徴とする請求項27に記載の製剤。
- 前記組成物は、ソラフェニブと同時に(simultaneous)、別に(separate)または順次に(sequential)投与されることを特徴とする請求項27に記載の製剤。
- 肝がんのソラフェニブ耐性抑制に使用するためのERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤。
- 肝がんの予防または治療に使用するためのERRγ(Estrogen-related receptorγ)タンパク質の活性またはERRγ遺伝子の発現を抑制できる製剤;およびソラフェニブを含む組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190152827 | 2019-11-26 | ||
KR10-2019-0152827 | 2019-11-26 | ||
PCT/KR2020/016976 WO2021107644A1 (ko) | 2019-11-26 | 2020-11-26 | 항암 효과 증진을 위한 ERRγ 억제제를 유효성분으로 포함하는 조성물의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023504786A true JP2023504786A (ja) | 2023-02-07 |
Family
ID=76129514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022530915A Pending JP2023504786A (ja) | 2019-11-26 | 2020-11-26 | 抗がん効果増進のためのERRγ抑制剤を有効成分として含む組成物の用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230017330A1 (ja) |
EP (1) | EP4066835A4 (ja) |
JP (1) | JP2023504786A (ja) |
KR (1) | KR102629125B1 (ja) |
CN (1) | CN114980897A (ja) |
AU (1) | AU2020392157A1 (ja) |
CA (1) | CA3159428A1 (ja) |
MX (1) | MX2022006280A (ja) |
WO (1) | WO2021107644A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230074982A (ko) * | 2021-11-22 | 2023-05-31 | 주식회사 노브메타파마 | 아릴에텐 화합물의 제조방법 |
KR20230146812A (ko) * | 2022-04-13 | 2023-10-20 | 재단법인 대구경북첨단의료산업진흥재단 | 아릴에텐 유도체를 유효성분으로 포함하는 염증성 장질환 치료용 조성물 |
WO2023233362A1 (en) * | 2022-06-02 | 2023-12-07 | Novmetapharma Co., Ltd. | Composition and method for treating cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160122850A (ko) * | 2014-02-28 | 2016-10-24 | 미르나 테라퓨틱스 인코포레이티드 | 간암에 대한 소라페닙-마이크로rna 병용 요법 |
CN105331584A (zh) * | 2014-08-06 | 2016-02-17 | 上海睿智化学研究有限公司 | 对索拉非尼具有耐药性或敏感性的人肝癌细胞系及其应用 |
KR101704533B1 (ko) * | 2014-10-13 | 2017-02-09 | 경북대학교병원 | 간암 바이오마커로서의 ERRγ 및 이의 용도 |
KR101751929B1 (ko) * | 2015-01-05 | 2017-06-28 | 서울대학교 산학협력단 | 신규 간암 환자의 소라페닙 저항성 예측 마커 |
CN106466306A (zh) * | 2015-08-19 | 2017-03-01 | 上海东方肝胆外科医院 | 含维甲酸和索拉非尼的药物组合物及其应用 |
KR101901001B1 (ko) * | 2015-12-30 | 2018-09-20 | 경북대학교 산학협력단 | PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물 |
KR20190042370A (ko) * | 2017-10-16 | 2019-04-24 | 한국과학기술원 | 소라페닙 저항성 암 치료제 |
CN109055549B (zh) * | 2018-08-01 | 2022-01-21 | 东南大学 | Trerna1基因在预测、提高肝癌药物索拉菲尼敏感性中的应用 |
-
2020
- 2020-11-26 JP JP2022530915A patent/JP2023504786A/ja active Pending
- 2020-11-26 CN CN202080082523.9A patent/CN114980897A/zh active Pending
- 2020-11-26 EP EP20894718.4A patent/EP4066835A4/en active Pending
- 2020-11-26 WO PCT/KR2020/016976 patent/WO2021107644A1/ko unknown
- 2020-11-26 CA CA3159428A patent/CA3159428A1/en active Pending
- 2020-11-26 AU AU2020392157A patent/AU2020392157A1/en active Pending
- 2020-11-26 KR KR1020200161456A patent/KR102629125B1/ko active IP Right Grant
- 2020-11-26 MX MX2022006280A patent/MX2022006280A/es unknown
- 2020-11-26 US US17/779,826 patent/US20230017330A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230017330A1 (en) | 2023-01-19 |
KR20210065064A (ko) | 2021-06-03 |
AU2020392157A1 (en) | 2022-06-23 |
CN114980897A (zh) | 2022-08-30 |
EP4066835A4 (en) | 2023-12-20 |
EP4066835A1 (en) | 2022-10-05 |
MX2022006280A (es) | 2022-08-15 |
WO2021107644A1 (ko) | 2021-06-03 |
KR102629125B1 (ko) | 2024-01-25 |
CA3159428A1 (en) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023504786A (ja) | 抗がん効果増進のためのERRγ抑制剤を有効成分として含む組成物の用途 | |
EP2820041B1 (en) | Iaspp phosphorylation and metastatic potential | |
JP2019531699A (ja) | Nrf2及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法 | |
US20210388040A1 (en) | Non-canonical swi/snf complex and uses thereof | |
US20170114124A1 (en) | SLIT-ROBO-Myo9-RHOA PATHWAY AND CANCER | |
US20210030836A1 (en) | Novel Tumor Microenvironment-Related Target TAK1 and Application Thereof in Inhibition of Tumor | |
US20160113911A1 (en) | Methods and compositions for the treatment of cancer | |
EP3336548B1 (en) | Method for providing information on chronic myeloid leukemia | |
JP2016000041A (ja) | 乳癌の診断を目的としたpax2の検出 | |
CN114736966A (zh) | 逆转乳腺癌耐药性的组合制剂及标志物应用 | |
US20210251998A1 (en) | Systems and methods for treating cancer | |
US20080318241A1 (en) | Methods and Systems for Detecting Antiangiogenesis | |
US20150323538A1 (en) | Systems and methods for diagnosing and treating cancer | |
KR20160010498A (ko) | 잠재적으로 hdac 억제제 치료를 필요로 하는 환자에서의 진단 및 예후 응용을 위한 유전자 발현 바이오마커 및 그들의 용도 | |
WO2011129427A1 (ja) | 癌の診断剤および治療剤 | |
JP7167263B2 (ja) | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 | |
WO2017091952A1 (zh) | Akt2在诊断和治疗肿瘤中的用途 | |
KR20170052454A (ko) | 소라페닙 민감성 예측용 바이오마커 조성물 | |
KR20220011349A (ko) | 간암 특이적 바이오 마커 및 이의 용도 | |
US10316319B2 (en) | Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof | |
KR102238258B1 (ko) | 간암 진단을 위한 신규 바이오마커 및 이를 이용한 치료 방법 | |
US20190055565A1 (en) | Prevention, diagnosis and treatment of cancer overexpressing gpr160 | |
WO2013183964A1 (ko) | 폐암 진단 및 치료를 위한 표적 단백질 | |
JP2010148501A (ja) | がんマーカー、及び、がんの治療剤 | |
KR102042332B1 (ko) | 간암의 재발 및 예후 예측용 tcirg1 마커 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240213 |